Sales to outside customers increased significantly to 13,884 million yen
(up 13.5% year-on-year).
The mainstay anti-inflammatory analgesic products continued to perform
well, partly owing to the launch of new products, and contributed to the
increase in sales. "Hadalabo Tokyo" also performed well in the
UK and key countries in Eastern Europe and the Middle East. In addition,
"Rohto Dry Aid," a dry eye ophthalmic solution that was launched
in 2021 after obtaining the CE marking, with which the Company continues
to develop the eye drop market, performed well.
Segment profit (operating profit basis) increased significantly to 1,385
million yen (up 41.6% year-on-year) owing to the impact of a significant
increase in sales and improvement of the cost of sales ratio.